OverviewSuggest Edit

Heron Therapeutics is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company’s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
TypePublic
Founded1983
HQSan Diego, US
Websiteherontx.com

Latest Updates

Employees (est.) (Feb 2020)231(+17%)
Job Openings4
Revenue (FY, 2019)$146 M(+89%)
Share Price (Nov 2020)$18.9 (+3%)
Cybersecurity ratingAMore

Key People/Management at Heron Therapeutics

Barry Quart

Barry Quart

Chief Executive Officer and Chairman of the Board
Kimberly Manhard

Kimberly Manhard

Executive VP, Drug Development and Director
John Poyhonen

John Poyhonen

President and Chief Commercial Officer
Chris Storgard

Chris Storgard

Chief Medical Officer
Stephen Davis

Stephen Davis

Director
Craig Johnson

Craig Johnson

Lead Independent Director
Show more

Heron Therapeutics Office Locations

Heron Therapeutics has offices in San Diego and Jersey City
San Diego, US (HQ)
4242 Campus Point Ct #200
Jersey City, US
101 Hudson St #2100
Show all (2)

Heron Therapeutics Financials and Metrics

Heron Therapeutics Revenue

Heron Therapeutics's revenue was reported to be $145.97 m in FY, 2019
USD

Revenue (Q3, 2020)

20.0m

Gross profit (Q3, 2020)

12.8m

Gross profit margin (Q3, 2020), %

64.1%

Net income (Q3, 2020)

(58.2m)

EBIT (Q3, 2020)

(58.4m)

Market capitalization (17-Nov-2020)

1.7b

Closing stock price (17-Nov-2020)

18.9

Cash (30-Sept-2020)

95.1m

EV

1.6b
Heron Therapeutics's current market capitalization is $1.7 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

646.0k1.3m30.8m77.5m146.0m

Cost of goods sold

35.0k4.6m27.5m61.6m

Gross profit

1.2m26.2m50.0m84.3m

Gross profit Margin, %

97%85%64%58%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

251.0k3.6m8.5m8.6m11.6m19.8m31.6m36.7m42.6m25.4m22.7m20.0m

Cost of goods sold

1.2m1.0m1.1m3.1m5.2m7.6m15.0m13.6m17.2m10.6m9.0m7.2m

Gross profit

2.4m7.5m7.5m8.4m12.2m16.6m23.1m25.4m14.8m13.7m12.8m

Gross profit Margin, %

67%88%88%73%62%53%63%60%58%60%64%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

18.0m53.5m72.3m72.7m75.2m13.4m144.6m31.8m71.9m

Accounts Receivable

2.0m41.9m64.7m39.9m

Prepaid Expenses

266.0k584.0k638.0k1.1m3.6m3.7m3.7m11.2m23.2m

Inventories

5.3m10.1m39.0m25.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

21.3m21.0m13.4m12.4m60.0m45.7m34.8m22.6m57.5m105.0m86.2m55.6m171.5m153.0m68.0m61.9m45.6m83.5m30.3m65.5m46.6m258.9m53.9m23.5m53.0m60.1m103.3m80.7m95.1m

Accounts Receivable

10.3m18.6m28.9m37.7m45.9m53.6m74.0m66.8m67.0m34.8m37.5m33.7m

Prepaid Expenses

499.0k301.0k306.0k557.0k355.0k427.0k360.0k763.0k2.3m518.0k3.0m945.0k1.9m2.0m5.1m3.2m3.1m3.4m3.7m4.6m5.5m6.6m10.2m11.5m8.7m16.7m12.4m13.1m16.4m

Inventories

2.7m3.3m2.0m4.6m4.8m5.2m19.4m27.2m31.4m31.4m29.3m24.2m34.8m41.4m42.7m
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Heron Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Heron Therapeutics Online and Social Media Presence

Embed Graph

Heron Therapeutics News and Updates

Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain

SAN DIEGO, July 24, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the...

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it...

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates

SAN DIEGO, March 2, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial...

Heron Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. ("Heron") (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced...

Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019

NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Heron Therapeutics, Inc. ("Heron" or the "Company") (NASDAQ: HRTX) and certain of its officers, on behalf of shareholders...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm

NEW YORK, July 12, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Heron Therapeutics, Inc. ("Heron") or the ("Company") (NASDAQ:HRTX) of the August 5, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Show more

Heron Therapeutics Blogs

Heron Therapeutics to Present at 2019 JMP Securities Life Sciences Conference

SAN DIEGO , June 13, 2019 /PRNewswire/ --  Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart,

Heron Therapeutics to Present at Jefferies 2019 Healthcare Conference

SAN DIEGO , May 29, 2019 /PRNewswire/ --  Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart,

Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management

Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management Content Import Mon, 04/01/2019 - 08:34 Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Posto…

77% of Patients Remain Opioid-Free When HTX-011 Is Given with an Over-the-Counter Analgesic Regimen in New Multi-center Postoperative Pain Management Study in Bunionectomy

- Bunionectomy Results Complement Opioid-Free Results from the Previously Reported Hernia Repair Study - SAN DIEGO , March 11, 2019 /PRNewswire/ --  Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing

Heron Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

SAN DIEGO , March 4, 2019 /PRNewswire/ --  Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that Barry Quart,

Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for IV Push

SAN DIEGO , Feb. 26, 2019 /PRNewswire/ --  Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S.
Show more

Heron Therapeutics Frequently Asked Questions

  • When was Heron Therapeutics founded?

    Heron Therapeutics was founded in 1983.

  • Who are Heron Therapeutics key executives?

    Heron Therapeutics's key executives are Barry Quart, Kimberly Manhard and John Poyhonen.

  • How many employees does Heron Therapeutics have?

    Heron Therapeutics has 231 employees.

  • What is Heron Therapeutics revenue?

    Latest Heron Therapeutics annual revenue is $146 m.

  • What is Heron Therapeutics revenue per employee?

    Latest Heron Therapeutics revenue per employee is $631.9 k.

  • Who are Heron Therapeutics competitors?

    Competitors of Heron Therapeutics include PainReform, Urovant Sciences and Cellestia Biotech.

  • Where is Heron Therapeutics headquarters?

    Heron Therapeutics headquarters is located at 4242 Campus Point Ct #200, San Diego.

  • Where are Heron Therapeutics offices?

    Heron Therapeutics has offices in San Diego and Jersey City.

  • How many offices does Heron Therapeutics have?

    Heron Therapeutics has 2 offices.